Regulators greenlight trials for Medicago-GSK vaccine in Brazil

GSK vaccine
GSK building. Photo: nitpicker/Shutterstock

Brazil’s federal health regulator Anvisa signed off on clinical trials for a new potential coronavirus vaccine, developed by pharmaceutical companies Medicago, from Canada, and GlaxoSmithKline (GSK), from the United Kingdom.

The vaccine will be administered in two shots, over a period of 21 days. Anvisa claims phase 1 and 2 trial data “presented a safety profile acceptable for potential vaccines.”

Phase 3 trials will include up to 30,000 volunteers in Canada, the U.S., Latin America, and Europe.